DZ Bank downgraded shares of Danaher (NYSE:DHR – Free Report) from a strong-buy rating to a hold rating in a research report released on Tuesday,Zacks reports.
Several other equities research analysts have also recently issued reports on the stock. Citigroup lifted their target price on shares of Danaher from $230.00 to $270.00 and gave the stock a “buy” rating in a research note on Thursday, October 22nd. The Goldman Sachs Group restated a “buy” rating and set a $275.00 price target on shares of Danaher in a research report on Thursday, October 22nd. Guggenheim boosted their target price on Danaher from $200.00 to $250.00 and gave the stock a “buy” rating in a report on Thursday, October 1st. Robert W. Baird upped their price target on Danaher from $246.00 to $254.00 and gave the company an “outperform” rating in a research report on Thursday, October 22nd. Finally, TD Cowen lifted their price objective on Danaher from $255.00 to $270.00 and gave the stock a “buy” rating in a research report on Thursday, October 22nd. Eighteen research analysts have rated the stock with a Buy rating and five have assigned a Hold rating to the company’s stock. According to data from MarketBeat.com, Danaher has an average rating of “Moderate Buy” and an average target price of $242.91.
Check Out Our Latest Stock Analysis on DHR
Danaher Price Performance
Shares of Danaher stock opened at $233.72 on Tuesday. The stock has a market capitalization of $164.43 billion, a P/E ratio of 38.25, a PEG ratio of 2.89 and a beta of 0.76. The business has a 50 day simple moving average of $218.10 and a two-hundred day simple moving average of $201.81. Danaher has a 12 month low of $160.93 and a 12 month high of $242.80. The company has a debt-to-equity ratio of 0.45, a current ratio of 1.63 and a quick ratio of 1.29.
Danaher (NYSE:DHR – Get Free Report) last issued its quarterly earnings results on Wednesday, October 21st. The conglomerate reported $2.11 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.92 by $0.19. Danaher had a return on equity of 11.17% and a net margin of 16.91%. The firm had revenue of $6.55 billion for the quarter, compared to analyst estimates of $6.56 billion. During the same period in the previous year, the company posted $1.89 earnings per share. The business’s revenue was up 8.3% on a year-over-year basis. As a group, analysts predict that Danaher will post 8.59 EPS for the current fiscal year.
Danaher Dividend Announcement
The business also recently announced a quarterly dividend, which will be paid on Friday, October 30th. Shareholders of record on Wednesday, September 30th will be given a $0.40 dividend. The ex-dividend date of this dividend is Wednesday, September 30th. This represents a $1.60 dividend on an annualized basis and a yield of 0.7%. Danaher’s dividend payout ratio is presently 26.19%.
Institutional Investors Weigh In On Danaher
A number of institutional investors and hedge funds have recently made changes to their positions in DHR. Main Street Group LTD acquired a new stake in Danaher in the 1st quarter valued at about $25,000. N.E.W. Advisory Services LLC acquired a new position in shares of Danaher in the 2nd quarter worth approximately $25,000. Marquette Asset Management LLC grew its stake in shares of Danaher by 192.1% in the 3rd quarter. Marquette Asset Management LLC now owns 111 shares of the conglomerate’s stock worth $25,000 after purchasing an additional 73 shares during the last quarter. Evolution Wealth Management Inc. raised its holdings in shares of Danaher by 208.0% in the 1st quarter. Evolution Wealth Management Inc. now owns 154 shares of the conglomerate’s stock worth $29,000 after purchasing an additional 104 shares in the last quarter. Finally, Field & Main Bank bought a new stake in shares of Danaher in the 2nd quarter worth approximately $29,000. 79.05% of the stock is owned by hedge funds and other institutional investors.
Danaher Company Profile
Danaher Corporation (NYSE: DHR) is a global science and technology company that develops products, services and solutions for the life sciences, biotechnology and diagnostics markets. Its offerings help researchers, pharmaceutical and biotechnology companies, healthcare providers and other organizations conduct scientific research, develop and manufacture medicines, and diagnose disease.
The company operates through businesses that provide bioprocessing equipment and technologies, laboratory instruments, consumables, analytical tools and clinical diagnostic systems.
Read More
- Five stocks we like better than Danaher
- Boeing Got Its MAX 10 Approval, But Q3 Delivered a Reality Check
- The Invisible AI Backbone: Corning’s AI Fiber Play
- Heavy Metal: Why Nucor Could Be an Overlooked AI Infrastructure Winner
- Why Tesla’s Upside Is About More Than a SpaceX Merger
Receive News & Ratings for Danaher Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Danaher and related companies with MarketBeat.com's FREE daily email newsletter.
